inGeneUs Biotech
Programming Genetic Software, The Code of Life
inGeneUs Biotech
Programming Genetic Software, The Code of Life
Biogenetics Resolving Inherited Diseases
30 years of addiction and dopamine deficiency research & 20 years of gene editing R&D are being applied to break the chain of inherited disorders.
Our Goal: To Prevent Inherited Epigenetic Disease
Our scientists identified a new field of science based on genetic mutations characterized by a clinically significant deficiency of dopamine.
Driven by 30 years of research, we pioneered Genetic Addiction Risk Severity (GARS), the first patented behavioral DNA test.
Our gene editing team is comprised of the top geneticists in the world, including the fathers of Behavioral Genetics & Trans-splicing
Driven by 25 years of research, we pioneered pro-dopamine neuronutrients, which regulate dopamine levels and treat addiction and behavioral disease
Developing a pipeline of synthetic molecules that will correct genetic mutations that cause disease. Currently entering animal-testing phase in humanized mice
Our geneticists have applied 20 years of R&D for gene editing to create a mRNA editing solution to prevent behavioral epigenetic disease caused by genetic mutation.
Technology that has been pre-clinically applied to 31 disease genes in human and animal cells. We have patented this technology for epigenetic mutations causing behavioral disease
mRNA editing technology for genetic disease with the goal of epigenetic regeneration — to develop genetic innovations resolving inherited disease
Collaborators include NIH, NIDA, National Human Genome Center, and industry-leading physicians and universities
The Problem: Behavioral Health & Addiction
1 in 5 US adults live with mental illness
1 in 12 with addiction with no major technological innovations in over 30 years
Our Vision of the Future
RNA repair or reprogramming is a new avenue for human gene therapy. The COVID-19 vaccines were a game changer with hundreds of millions around the world using a mRNA health vaccine for COVID. 20 years of research towards gene editing is now being applied to address addiction and mental health affecting almost 100 million US citizens.
inGeneUs Biotech scientists are bringing neurobiology, neuropharmacology, biogenetics, psychiatry, and medicine moving forward in close coordination to reduce the devastating behavioral and social costs of faulty brain functions.
We see a future world where each individual will be able to enjoy the inborn legacy of reward and pleasure without having the need for addictive substances and without having to pay the price of addiction and pain.
RNA Trans Splicing Gene Editing Technology
Our world-class team of scientists have developed and patented RNA editing SMaRT™ technology, allowing for significant breakthroughs in disease and disorder management. SMaRT™ technology can reprogram the vast majority of genes to correct genetic errors, confer a new function to a cell, or create novel gene products.
SMaRT™ technology has broad applications including gene reprogramming, RNA repair, real-time molecular imaging, and genomics. It has developed a broad collaborative network with a number of renowned institutions including the National Heart, Lung and Blood Institute of the National Institutes of Health; the University of Iowa; Stanford University; and King’s College London.
RNA trans splicing is one of a handful of techniques that can convert the expression of a dominant negative mutation into the normal protein thus simultaneously reducing the cause of the disease and increasing the amount of a necessary protein. Trans splicing is the only method that can achieve these results without the requirement for cell division.
Epigenetic Regeneration for Behavioral Health
Four leading genetic scientists have come together to create the first mRNA editing technology for behavioral health. The goal of inGeneUs Biotech is epigenetic regeneration — to develop gentech
innovations to resolve addictive substance (drugs, alcohol, glucose) and non-substance disorders (anxiety, stress, depression, gambling).
inGeneUs Biotech was formed to develop mRNA molecules related to the underpinnings of all addictive disorders, both drug and non-drug behaviors. We are currently in the pretrial clinical stage of development.
Collaborators include the NIH, NIDA, National Human Genome Center, and industry leaders in addiction and genomics.
